– Chassis to present A concept video introducing Cureca ™ to Escmid Global 2025 – a complete automation system expected To cover the entire PCR workforce, from the pre-treatment of samples to the analysis of the results.
– Designed for 24 hours, seven days a week, unattended, Cureca ™ reflects the company’s mission to set a new global standard and advance its vision of a “world without all diseases”.
Seoul, South Korea,, April 9, 2025 / Prnewswire / – Seegene Inc., a world leader in molecular diagnosis (MDX), advances its vision of laboratory innovation with the development of Cureca ™ – a new generation system currently in development, designed to rationalize automation in polymerase chain reaction tests (PCR) and laboratory environments.
The company has announced today that it would present a conceptive video introducing the Cureca ™ system of the European Company of Clinical Microbiology and Infectious Diseases (Escmid Global 2025), held April 11-15 In Vienna, Austria. The video will describe the design objectives of the system and will consider a workflow. A physical demonstration of the system should take place July 2025 to the association for diagnostics & laboratory medicine (ADLM 2025) Chicago.
CURECA ™ – Abbreviation of unlimited continuous random access Extensible and customizable full automation – is the PCR test solution envisaged from Seegene, intended to allow complete automation of the PCR test workflow. The system should include two main components: the customizable pre -treatment system (CPS), responsible for loading samples and pre -treatment treatment; And complete customizable and extensible automation (CEFA), which would carry out the sample load and the preparation of nucleic acid extraction, the configuration of the PCR, the amplification of the genes and the analysis of the results.
Complete pioneer of automation of PCR pre -treatment treatment
The pre -treatment stage in MDX requires careful handling of various types of samples – such as stool, urine, blood and expectorations – as well as sorting different container formats. Traditionally, this process has strongly supported manual work by trained laboratory professionals.
Seegene aims to direct innovation in the automation of pre -treatment treatment for all types of PCR samples thanks to the development of CPS. The system is designed to automate key steps such as sorting of samples, centrifugation, vortex and heat treatment. The CPS can also operate independently of the complete Cureca ™ system and be applied to other areas of laboratory test such as hematology, biochemistry and immunodiagnostics – expanding its potential usefulness in clinical workflows.
The modular design of Cureca ™ is intended to provide laboratories with flexibility to configure the system according to their operational needs. By supporting automation through the full work flow, the system aims to reduce the risk of human error and to allow PCR tests with continuous high speed 24 hours a week.
At Escmid Global 2025, Seegene will present a conceptual video simulating the complete work flow of PCR automation – the loading of samples and the treatment of pre -treatment for nucleic acid extraction, the configuration of the PCR, the amplification of the genes and the analysis of the results. The presentation will further highlight the adaptability of the system in different laboratory environments and test capacities.
Cureca ™ to support Seegene’s vision of “a world free of all diseases”
“Until now, there has not been a system capable of completely automating pre -treatment for all types of samples, which has prevented real automation in MDX,” said Dr. Jong-Yoon Chunfounder and CEO of Seegene. “We aim to define a new world reference and reshape the future of MDX.”
Dr. Chun also noted that Cureca ™ is planned to support the global SEEGENE technology sharing initiative, which aims to make the MDX advanced more accessible and better integrated into daily health care in the world. “Cureca ™ marks a first step towards the progress of Seegene’s vision to create” a world free of all diseases “. We will continue to lead through innovation and global collaboration to advance this vision.”
Chassis to underline “Redefine MDX” to Escmid 2025
Seegene will present its syndromic PCR dosage portfolio in real time under the theme “Redefine MDX” to Escmid Global 2025, including the validated test solutions currently used. The company will also organize symposium sessions during the conference, exploring the evolutionary role of MDX in the fight against resistance to antimicrobials (AMR) and the needs for diagnostic of change in the post-19th era. Featured tests, such as drug resistance (Entero DR) and sexually transmitted infection – Antimicrobial resistance (Sti -AMR), are designed to support more informed and more timely treatment decisions.
ARout Abouther
Seegene has more than 20 years of experience dedicated to R&D, manufacturing and business linked to real -time PCR technologies in real time. This expertise was particularly highlighted during the COVVI-19 pandemic when Seegene provided more than 340 million COVID-19 tests to more than 100 countries around the world. The main characteristic of Seegene’s real -time PCR syndromic technology is the ability to test 14 pathogens simultaneously that cause similar symptoms in a single tube with quantitative information.
Visit: Seegene.com and follow Linkedin.com/company/seegene-incin
Technological sharing initiative
The technology sharing initiative aims to share with advanced SEEGENE diagnostic and data analysis technologies, including real -time PCR in real time and an automated product development system (SGDD), with a leading company in each country. Partnership companies will collaborate with local scientists and experts to develop diagnostic tests adapted to the needs of their communities and their areas, covering a wide range of human and non -human diseases. The ultimate vision of the initiative is to create “a world free from diseases” – a future where people no longer suffer from infectious diseases and cancer, and where animals and plants thrive without illness.
Source Sense inc.
